Actelion (XSWX:ATLNE) FCF Yield % : 3.03 (As of May. 01, 2024)

View and export this data going back to . Start your Free Trial

What is Actelion FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Actelion's Trailing 12-Month Free Cash Flow is CHF890 Mil, and Market Cap is CHF7,849 Mil. Therefore, Actelion's FCF Yield % for today is 3.03%.

The historical rank and industry rank for Actelion's FCF Yield % or its related term are showing as below:

XSWX:ATLNE' s FCF Yield % Range Over the Past 10 Years
Min: 0.51 Med: 4.04 Max: 11.11
Current: 3.03

During the past 13 years, the highest FCF Yield % of Actelion was 11.11%. The lowest was 0.51%. And the median was 4.04%.

XSWX:ATLNE's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -14.81 vs XSWX:ATLNE: 3.03

Actelion's FCF Margin % for the quarter that ended in Mar. 2017 was 30.09%.

Actelion FCF Yield % Historical Data

The historical data trend for Actelion's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion FCF Yield % Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

FCF Yield %

Get a 7-Day Free Trial

10.16

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
FCF Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Actelion's FCF Yield %

For the Biotechnology subindustry, Actelion's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actelion's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Actelion's FCF Yield % falls into.

Actelion FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Actelion's FCF Yield % for the fiscal year that ended in Dec. 2016 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	862.088	/	0
	=	N/A%

Actelion's annualized FCF Yield % for the quarter that ended in Mar. 2017 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	194.434	*	4	/	0
	=	N/A%

Actelion FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Actelion FCF Yield % Related Terms

Thank you for viewing the detailed overview of Actelion's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (XSWX:ATLNE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines